April 11, 2011 11:08 ET

Cancer Supportive Care Market Expected to Decline Due to Generic Erosion

ROCKVILLE, MD--(Marketwire - Apr 11, 2011) - has announced the addition of GBI Research's new report "Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars" to their collection of Therapeutic Area market reports. For more information, visit

In 2009, the global cancer supportive care products market was valued at $11 billion, up from $7.5 billion in 2001, indicating a CAGR (Compounded Annual Growth Rate) of 5% between 2001 and 2009. The major drivers of the growth had been the launch of new and better treatment medications, increased prevalence of cancer and a resulting increase in chemotherapy patient populations.

In future, the global cancer supportive care products market is expected to reach $12.6 billion, indicating a CAGR of 2% during the period 2009-2016. The market will grow until 2014 at a growth rate of approximately 3- 5%, followed by a decline of approximately 1.2% until 2016 due to the patent expiry of leading drugs across all major markets. Some of the major drugs that are expected to lose patent protection between 2013 and 2016 include Neupogen (filgrastim), Neulasta (pegfilgrastim), Aranesp (darbepoetin alfa), Procrit (epoetin alfa), Emend (aprepitant), Zometa (zoledronic acid) and Aloxi (palonosetron hydrochloride). Thus, patent expiries coupled with a weak development pipeline will be the major factors behind the sluggish growth of the cancer supportive care products market in future.

Bone metastases, oral mucositis and dry mouth, and cancer pain therapeutics are the sectors estimated to demonstrate significant growth in future among all the segments of the global cancer supportive care products market. Between 2009 and 2016, the bone metastases therapeutics market will be the fastest growing market segment, and is expected to reach $1.2 billion in 2016 from $690m in 2009, indicating a CAGR of 8.1%. Increased uptake of novel monoclonal antibody, Xgeva (denosumab), which received approval for bone metastases in cancer patients in November 2010, is expected to be the principal driver for the market. In addition, an increasing prevalence population is also expected to drive the market in future. On the other hand, the oral mucositis and dry mouth therapeutics market is expected to witness a CAGR of 5.9% between 2009 and 2016 to reach $2.1 billion in 2016 from $1.4 billion in 2009.

High unmet need in terms of efficacious drugs and the increasing prevalence of the disease are expected to be the major drivers of the global oral mucositis and dry mouth therapeutics market in the future. The cancer pain therapeutics market will witness a CAGR of 5.3% between 2009 and 2016, driven by increasing prescription rates and new modes of delivery of cancer pain drugs that will help in the better management of pain for a longer duration. These factors are expected to drive the global cancer pain therapeutics market from $2 billion in 2009 to $2.9 billion in 2016.

For more information, visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact